Biodistribution of AAV1, AAV5, AAV9, and AAVDJ serotypes after intra-cisterna magna delivery in non-human primates
Molecular Therapy Methods & Clinical Development · 2025-12 · 33 (4) · 101593
DOI: 10.1016/j.omtm.2025.101593 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Methods & Clinical Development, 2025-12. Verfasst von Takuro Okai und 12 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa 251-8555, Japan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Takeda Pharmaceutical Company Limited.
Abstract (Originalsprache)
Delivering drugs effectively to the central nervous system (CNS) is a major challenge in drug development, including adeno-associated virus (AAV) gene therapy. The cerebrospinal fluid (CSF) circulates through the ventricular system and the subarachnoid space, surrounding both the brain and spinal cord, making it an attractive target for CNS drug delivery. Here, we compare intra-cisterna magna (ICM) administration of four AAV serotypes, AAV1, AAV5, AAV9, and AAVDJ, carrying glucosylceramidase beta 1 (GBA1) cDNA encoding the lysosomal enzyme β-glucocerebrosidase (GCase), in non-human primates (NHPs). Mutations in GBA1 are causative for Gaucher's disease (GD) and the most important genetic risk factor for Parkinson's disease (PD). AAV delivery of GBA1 is a promising therapeutic approach for GD and PD, assuming effective delivery to the target tissues. Our data show no significant difference in biodistribution among AAV serotypes. ICM administration effectively delivers GCase to the spinal cord and dorsal root ganglia, though distribution to deep brain regions is limited. The ICM procedure was well tolerated with no significant toxicity. To improve delivery to deep brain regions, AAVs with blood-brain barrier (BBB)-penetrating capabilities, protein-engineered GCase enzymes optimized for secretion and cross-correction, or delivery methods such as convection-enhanced delivery or ultrasound-focused technology may be required.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa 251-8555, Japan.
- Center of Excellence for Drug Metabolism, Pharmacokinetics and Modeling, Preclinical and Translational Sciences, Research, Takeda Pharmaceutical Company Limited, Fujisawa 251-8555, Japan.
- Drug Safety Research and Evaluation, Preclinical and Translational Sciences, Research, Takeda Pharmaceutical Company Limited, Fujisawa 251-8555, Japan.
- Takeda Development Center Americas, Cambridge, MA 02142, USA.
- Neuroscience Drug Discovery Unit, Research, Takeda Development Center Americas, Inc, Cambridge, MA 02142, USA.
Förderung
- Takeda Pharmaceutical Company Limited
Zitieren
APA
Okai, T., Sato, S., Yasuno, H., Nakayama, M., Yamamoto, S., Sjöqvist, S., Otake, K., Nakashima, M., Deshpande, M., Galbreath, E., Oak, J. H., Miyamoto, S., & Proetzel, G. (2025). Biodistribution of AAV1, AAV5, AAV9, and AAVDJ serotypes after intra-cisterna magna delivery in non-human primates. Molecular Therapy Methods & Clinical Development, 33(4), 101593. https://doi.org/10.1016/j.omtm.2025.101593
Vancouver
Okai T, Sato S, Yasuno H, Nakayama M, Yamamoto S, Sjöqvist S, et al. Biodistribution of AAV1, AAV5, AAV9, and AAVDJ serotypes after intra-cisterna magna delivery in non-human primates. Molecular Therapy Methods & Clinical Development. 2025;33(4):101593. doi:10.1016/j.omtm.2025.101593
BibTeX
@article{Okai2025,
author = {Okai, Takuro and Sato, Sho and Yasuno, Hironobu and Nakayama, Miyu and Yamamoto, Syunsuke and Sjöqvist, Sebastian and Otake, Kentaro and Nakashima, Masato and Deshpande, Mugdha and Galbreath, Elizabeth and Oak, Jeong-Ho and Miyamoto, Saku and Proetzel, Gabriele},
title = {Biodistribution of AAV1, AAV5, AAV9, and AAVDJ serotypes after intra-cisterna magna delivery in non-human primates},
journal = {Molecular Therapy Methods & Clinical Development},
year = {2025},
volume = {33},
number = {4},
pages = {101593},
doi = {10.1016/j.omtm.2025.101593}
}
EUVIMED